Clinical guideline · 2022
Disorders of Ejaculation: An AUA/SMSNA Guideline
Shindel AW, Althof SE, Carrier S, Chou R, McMahon CG, Mulhall JP, Paduch DA, Pastuszak AW, Rowland D, Tapscott AH, Sharlip ID (2022). Disorders of Ejaculation: An AUA/SMSNA Guideline. The Journal of Urology. doi:10.1097/JU.0000000000002392
Based on a systematic review of 8 systematic reviews and 59 studies, the AUA/SMSNA guideline found psychological, behavioural and drug options for PE, notes that no drug is FDA-approved for it (use is off-label) and recommends shared decision-making.
Summary
This guideline from the American Urological Association (AUA) and the Sexual Medicine Society of North America (SMSNA) covers premature ejaculation (PE) and delayed ejaculation. The guideline was first released by the AUA in 2020; this journal publication appeared in 2022. It was informed by a systematic review carried out by the Pacific Northwest Evidence-based Practice Center, which screened 1,851 potentially relevant articles and included 8 systematic reviews and 59 individual studies.
The panel concluded that several psychological, behavioural and pharmacological options exist for PE, but that none of the medications has approval from the US Food and Drug Administration for this use, so their use in the United States is off-label. It describes the clinician's role as investigating appropriately, providing education and offering treatments that are rational and based on sound data. Shared decision-making is recommended as fundamental, and involving the sexual partner in decisions, where possible, may improve outcomes.
The guideline statements on the AUA website (checked 8 October 2026) include: clinicians should recommend daily SSRIs (selective serotonin reuptake inhibitors), on-demand clomipramine or dapoxetine (where available), and topical penile anaesthetics as first-line pharmacotherapies (Statement 9); clinicians may consider on-demand tramadol in men who have failed first-line pharmacotherapy (Statement 10); clinicians should treat comorbid erectile dysfunction according to the AUA guideline on erectile dysfunction (Statement 12); and clinicians should advise that combining behavioural and pharmacological approaches may be more effective than either alone (Statement 13).
Limitations
The literature search ran to 2019, so newer trials are not included. The published abstract summarises the recommendations only broadly; the statements quoted above come from the guideline on the AUA website, and their evidence grades and supporting discussion are in the full guideline. The regulatory point about drug approval applies to the United States; dapoxetine, for example, is approved in a number of other countries.
What it means for you
US urology guidance treats PE as a real, manageable condition with more than one route: education, behavioural and psychological approaches, and off-label medication. The recommended way to choose between them is a joint decision with your clinician, ideally with your partner involved.